Making a drug more convenient to take by producing an extended-release version can help drive sales. But things become more complicated when the extended-release version has to compete with a generic immediate-release version. Popping twice as many pills may be an acceptable trade-off for patients if the copay for the drug is cheaper.
But Impax has one big advantage: IPX066 appears to work much better than immediate-release carbidopa-levodopa. In phase 3 data released yesterday afternoon, IPX066 substantially improved symptoms of Parkinson's disease patients compared to the immediate-release version. Reducing the number of times the drug had to be taken from five times a day down to about 3.5 times per day was just an added bonus.
There are already generic versions of the extended-release version of the combo, Sinemet CR, which was originally developed by Merck
Impax plans to file its marketing application to the Food and Drug Administration in the fourth quarter. It'll market the drug on its own in the U.S., where it already has a sales force in place because it has a co-promotion agreement with Pfizer
We'll get a better look at the data at upcoming medical meetings, but considering the data we've seen so far, it doesn't look like Impax should have any problems getting IPX066 approved.
Interested in keeping track of Impax as it goes for an FDA approval of IPX066? Click here to add it to My Watchlist, which will help you keep track of all our Foolish analysis on the stock.
Pfizer is a Motley Fool Inside Value pick. GlaxoSmithKline and Novartis are Motley Fool Global Gains recommendations. The Fool owns shares of GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
More from The Motley Fool
Why Impax Laboratories Inc Is Tanking Today
Traders flee after the company announces that it is merging with a privately held drugmaker.
Why Calgon Carbon, Kindred Healthcare, and Impax Laboratories Jumped Today
These stocks defied a downward-moving market. Find out why.
Why Impax Laboratories Inc Is Up for a Second Straight Day
Analysts upped their price targets following a solid second-quarter report from the drugmaker.